MD4349C1 - N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation - Google Patents

N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation

Info

Publication number
MD4349C1
MD4349C1 MDA20140062A MD20140062A MD4349C1 MD 4349 C1 MD4349 C1 MD 4349C1 MD A20140062 A MDA20140062 A MD A20140062A MD 20140062 A MD20140062 A MD 20140062A MD 4349 C1 MD4349 C1 MD 4349C1
Authority
MD
Moldova
Prior art keywords
human melanoma
compound
hydrazinecarbothioamide
ylmethylene
mew
Prior art date
Application number
MDA20140062A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD4349B1 (en
Inventor
Аурелиан ГУЛЯ
Анджей ЛИПКОВСКИЙ
Ольга ГАРБУЗ
Джоанна МАТАЛИНСКА
Виктор ЦАПКОВ
Original Assignee
Государственный Университет Молд0
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственный Университет Молд0 filed Critical Государственный Университет Молд0
Priority to MDA20140062A priority Critical patent/MD4349C1/en
Publication of MD4349B1 publication Critical patent/MD4349B1/en
Publication of MD4349C1 publication Critical patent/MD4349C1/en

Links

Abstract

The invention relates to chemistry and medicine, namely to an organic compound from the class of thioamides, which may find application in medicine as a cytostatic agent for the prophylaxis and treatment of human melanoma.Summary of the invention consists in the synthesis of N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound of formula:,exhibiting the human melanoma MeW-164 cell proliferation inhibition property.
MDA20140062A 2014-06-23 2014-06-23 N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation MD4349C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20140062A MD4349C1 (en) 2014-06-23 2014-06-23 N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20140062A MD4349C1 (en) 2014-06-23 2014-06-23 N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation

Publications (2)

Publication Number Publication Date
MD4349B1 MD4349B1 (en) 2015-05-31
MD4349C1 true MD4349C1 (en) 2015-12-31

Family

ID=53190461

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140062A MD4349C1 (en) 2014-06-23 2014-06-23 N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation

Country Status (1)

Country Link
MD (1) MD4349C1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4520C1 (en) * 2016-12-16 2018-05-31 Государственный Университет Молд0 N-(4-butoxyphenyl)-2-(pyridin-2-ylmethylidene)hydrazinecarbothioamide as T-47D breast cancer cells growth inhibitor

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281715A (en) * 1992-05-13 1994-01-25 Yale University 2-formylpyridine thiosemicarbazone compounds
CN101260121A (en) * 2007-03-07 2008-09-10 卡南吉医药科技（上海）有限公司 Complex compound of heteroaromatic thiosemicarbazone and transition metal, and application thereof in preparing antineoplastic medicine
MD3655G2 (en) * 2007-09-03 2009-02-28 Государственный Университет Молд0 Inhibitor of human myeloid leukemia on base of bis(2-hydroxy-8-phenyl-tricyclo/7.3.1.0.2,7/-tridecane-13-on-thiosemicarbazonato)copper
MD3771G2 (en) * 2008-04-30 2009-07-31 Государственный Университет Молд0 Inhibitors of 17β-HSD enzyme, stimulator for prostate cancer cell multiplication
MD3995B1 (en) * 2009-05-11 2009-12-31 Universitatea De Stat Din Moldova Use of di(Á-Ophenoxy)-di{[2-(4-aminobenzenesulfamido)-5-ethyl-1,3,4-thiadiazole]-3,5-dibromosalicylidenethiosemicarbazonato(-1)-copper} as inhibitor of mammary cancer T-47D cell proliferation
MD3890G2 (en) * 2008-09-08 2009-12-31 Государственный Университет Молд0 Inhibitors of human myeloid leukemia on base of coordinative compounds of copper(II) with salicylidene thiocarbazides
MD3996B1 (en) * 2009-05-25 2009-12-31 Universitatea De Stat Din Moldova Perchlorates of 5-R-salicylidene-4-phenylthiosemicarbazonato(1-)-aquacopper(II) possessing properties of inhibitors of 17Beta-HSD enzyme activity (type 1)
WO2010006438A1 (en) * 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CN102210698A (en) * 2004-01-02 2011-10-12 维奥恩药品公司 Use of composition containing 3-aminopyridine-2-formaldehyde thiosemicarbazone in treatment of cancers
MD4190B1 (en) * 2011-06-16 2012-12-31 Univ De Stat Din Moldova Inhibitor of human myeloid leukemia based on {bis¢2-(3,5-dibrom-2-hydroxyphenyl)-2-oxoethyl-piperidin-1-carbodithioato(1-)-O,O′]copper}
MD4215B1 (en) * 2012-07-09 2013-04-30 Univ De Stat Din Moldova Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281715A (en) * 1992-05-13 1994-01-25 Yale University 2-formylpyridine thiosemicarbazone compounds
US5721259A (en) * 1992-05-13 1998-02-24 Yale University Method of using 2-formylpyridine thiosemicarbazone compounds
CN102210698A (en) * 2004-01-02 2011-10-12 维奥恩药品公司 Use of composition containing 3-aminopyridine-2-formaldehyde thiosemicarbazone in treatment of cancers
CN101260121A (en) * 2007-03-07 2008-09-10 卡南吉医药科技（上海）有限公司 Complex compound of heteroaromatic thiosemicarbazone and transition metal, and application thereof in preparing antineoplastic medicine
MD3655G2 (en) * 2007-09-03 2009-02-28 Государственный Университет Молд0 Inhibitor of human myeloid leukemia on base of bis(2-hydroxy-8-phenyl-tricyclo/7.3.1.0.2,7/-tridecane-13-on-thiosemicarbazonato)copper
MD3771G2 (en) * 2008-04-30 2009-07-31 Государственный Университет Молд0 Inhibitors of 17β-HSD enzyme, stimulator for prostate cancer cell multiplication
WO2010006438A1 (en) * 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
MD3890G2 (en) * 2008-09-08 2009-12-31 Государственный Университет Молд0 Inhibitors of human myeloid leukemia on base of coordinative compounds of copper(II) with salicylidene thiocarbazides
MD3995B1 (en) * 2009-05-11 2009-12-31 Universitatea De Stat Din Moldova Use of di(Á-Ophenoxy)-di{[2-(4-aminobenzenesulfamido)-5-ethyl-1,3,4-thiadiazole]-3,5-dibromosalicylidenethiosemicarbazonato(-1)-copper} as inhibitor of mammary cancer T-47D cell proliferation
MD3996B1 (en) * 2009-05-25 2009-12-31 Universitatea De Stat Din Moldova Perchlorates of 5-R-salicylidene-4-phenylthiosemicarbazonato(1-)-aquacopper(II) possessing properties of inhibitors of 17Beta-HSD enzyme activity (type 1)
MD4190B1 (en) * 2011-06-16 2012-12-31 Univ De Stat Din Moldova Inhibitor of human myeloid leukemia based on {bis¢2-(3,5-dibrom-2-hydroxyphenyl)-2-oxoethyl-piperidin-1-carbodithioato(1-)-O,O′]copper}
MD4215B1 (en) * 2012-07-09 2013-04-30 Univ De Stat Din Moldova Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Anuszewska E., Chlopkiewicz B., Gruber B., Marczewska J., Priebe W., Skurzak H. Estimation of DNA damage and cytotoxicity of anthracycline analogs in human melanoma cells on early and late passages. Acta Poloniae Pharmaceutica - Drug Research, 2006, vol. 63, nr. 4, p. 321-324 *
Douglas West, Jack Ingram, Nicole Kozub, Gordon Bain, Anthony Liberta. Copper(II) complexes of 2-formyl-, 2-acetyl- and 2-benzoyl-pyridine N(4)-phenyl-, N(4)-o-methoxyphenyl-, N(4)-p-methoxy-phenyl- and N(4)-p-nitrophenylthiosemicarbazones. Transition Metal Chemistry, June 1996, vol. 21, issue 3, p. 213-218 (regăsit în Internet la 2015.02.10 URL:<http://link.springer.com/content/pdf/10.1007/BF00165969.pdf#>) *
Douglas X. West et al. Copper(II) complexes of 2- formyl-, 6-methyl-2-formyl- and 2- benzoylpyridine N(4)-(2-methylpyridinyl)-, N(4)- (2-ethylpyridinyl)- and N(4)-methyl(2- ethylpyridinyl)thiosemicarbazones. Transition Metal Chemistry, 1996, 21, 289-295; (regăsit în Internet la 2015.02.11 URL: <http://www.springerlink.com/content/g90np851733v87lk/>) *
Giorgio Pelosi. Thiosemicarbazone Metal Complexes: from structure to activity. The Open Crystallography Journal, 2010, 3, pag. 16-28, (regăsit în Internet la 2015.02.10 URL: < <http://benthamopen.com/contents/pdf/TOCRYJ/TOCRYJ-3-16.pdf>>) *

Also Published As

Publication number Publication date
MD4349B1 (en) 2015-05-31

Similar Documents

Publication Publication Date Title
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
MX2016015743A (en) Cyclopropylamine compounds as histone demethylase inhibitors.
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
PH12017502141A1 (en) Compounds and their methods of use
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
TW201613911A (en) Heterocyclic compounds and uses thereof
MX2018002402A (en) Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators.
MX2017004200A (en) Heteroaryl compounds as btk inhibitors and uses thereof.
UA116648C2 (en) FUMARATS AS A PRODUCT AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES
CL2014002873A1 (en) Compounds derived from pyrimidin-amine or triazin-amine, adn-pk inhibitors; pharmaceutical composition; and its use for the treatment of cancer.
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
MX2015013042A (en) Organic compounds.
MX2016002794A (en) Antiproliferative compounds.
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
BR112017000730A2 (en) pyrrolidinone derivatives as metap-2 inhibitors
MX370412B (en) Antimycotic compound.
MX2017007377A (en) Organic compounds.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX362896B (en) Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer.
MX2015016332A (en) Pyrrolotriazines as alk inhibitors.
EA201270728A1 (en) PURINE CONNECTIONS
MX2017007380A (en) Organic compounds.
MD4349B1 (en) N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation
EA201270727A1 (en) PURINE CONNECTIONS

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees